Synthesis and Biological Evaluation of N-3-Alkyl-Thienopyrimidin-4-Ones as mGluR1 Antagonists
- Authors
- Kim, Minjoo; Kim, Youngjae; Seo, Seon Hee; Baek, Du-Jong; Min, Sun-Joon; Keum, Gyochang; Choo, Hyunah
- Issue Date
- 2015-05
- Publisher
- WILEY-V C H VERLAG GMBH
- Citation
- BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.36, no.5, pp.1439 - 1451
- Abstract
- Metabotropic glutamate receptor subtype 1 (mGluR1) is a potential target for the treatment of neuropathic pain, and there has been much effort to discover mGluR1 antagonists. In this study, a series of N-3-alkyl-thienopyrimidin-4-ones were prepared by introducing various alkyl and aryl groups to the N-3- and 7-positions of the thienopyrimidin-4-one core structure, respectively, and their inhibitory activities against mGluR1 were biologically evaluated. Structure-activity relationship study revealed that the trans-4-methylcyclohexyl, cycloheptyl, and cyclooctyl groups at N-3-position, and 2-fluorophenyl group at 7-position were most effective in potentiating the inhibitory activity of the thienopyrimidin-4-one derivatives against mGluR1. Among the synthesized compounds, 3-cyclooctyl-7-phenylthienopyrimidin-4-one and 3-cycloheptyl-7-(2-fluorophenyl)thienopyrimidin-4-one exhibited the most potent inhibitory activities with IC50 values of 115 and 107 nM, respectively.
- Keywords
- METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-COUPLED RECEPTORS; RAT-BRAIN; GROUP-I; PAIN; PHARMACOLOGY; EXPRESSION; KNOCKDOWN; BEHAVIOR; DISEASE; METABOTROPIC GLUTAMATE RECEPTORS; PROTEIN-COUPLED RECEPTORS; RAT-BRAIN; GROUP-I; PAIN; PHARMACOLOGY; EXPRESSION; KNOCKDOWN; BEHAVIOR; DISEASE; mGluR1 Antagonist; N-3-Alkyl-thienopyrimidin-4-one; CNS disease; Neuropathic pain; Glutamate
- ISSN
- 0253-2964
- URI
- https://pubs.kist.re.kr/handle/201004/125521
- DOI
- 10.1002/bkcs.10283
- Appears in Collections:
- KIST Article > 2015
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.